Register Login

Xilio Therapeutics Inc. (XLO)

(10% Negative) Xilio Therapeutics, Inc. (XLO) Announces Delay in million Trials for gross proceeds from Series B warrant exercises Due to Geopolitical Situation, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 8, 2026, 1:44 p.m.

    📋 Xilio Therapeutics, Inc. (XLO) - Clinical Trial Update

    Filing Date: 2026-01-08

    Accepted: 2026-01-08 08:42:57

    Event Type: Clinical Trial Update

    Event Details:

    Xilio Therapeutics Inc. (XLO) Announces Clinical Trial Update Xilio Therapeutics Inc. (XLO) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: million
    • Diseases/Conditions: gross proceeds from Series B warrant exercises
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Geopolitical Situation, Regulatory Process
    • Collaboration: Gilead Sciences, Inc.
      • targeting the tumor-associated antigen for CLDN18.2, which has broad potential as a target for gastric, pancreatic, esophageal and lung cancers.•The appointment of Sara M. Bonstein as chair of the board of directors of Xilio. Ms. Bonstein has served as a member of Xilio’s board of directors since August 2021
      • targeting CLDN18.2 Appoints Sara Bonstein as chair of board of directors WALTHAM, Mass., Jan. 8, 2026

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Xilio Therapeutics Inc.
    • CIK: 0001840233
    • Ticker Symbol: XLO
    • Period End Date: 2026-01-06
    • Document Type: 8-K

Search

News categories